Status: Recruiting
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.
Participants needed: 100
Trial details
Phase: Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.Updated: Dec 10, 2024Locations: 1
Eligibility criteria
Participate in the study voluntarily, sign the informed consent form. [+5]
With untreated brain metastasis or concomitant meningeal metastasis and spinal c... [+7]